Antipsychotic Use in Dementia 1999-2007
Helen C. Kales, MD; Kara Zivin, PhD; Hyungjin Myra Kim, ScD; Marcia Valenstein, MD; Claire Chiang, MD; Rosalindo Ignacio, MS; Dara Ganoczy, MPH; Francesca Cunningham, PharmD; Lon S. Schneider, MD; Frederic C. Blow, PhD
Arch Gen Psychiatry. 2011;68(2):190-197. doi:10.1001/archgenpsychiatry.2010.200
Context Use of atypical antipsychotics for neuropsychiatric symptoms of dementia increased markedly in the 1990s. Concerns about their use began to emerge in 2002, and in 2005, the US Food and Drug Administration warned that use of atypical antipsychotics in dementia was associated with increased mortality.
Objective To examine changes in atypical and conventional antipsychotic use in outpatients with dementia from 1999 through 2007.
Design Time-series analyses estimated the effect of the various warnings on atypical and conventional antipsychotic usage using national Veterans Affairs data across 3 periods: no warning (1999-2003), early warning (2003-2005), and black box warning (2005-2007).
Subjects Patients aged 65 years or older with dementia (n = 254 564).
Main Outcome Measures Outpatient antipsychotic use (percentage of patients, percentage of quarterly change, and difference between consecutive study periods).
Results In 1999, 17.7% (95% confidence interval [CI], 17.2-18.1) of patients with dementia were using atypical or conventional antipsychotics. Overall use began to decline during the no-warning period (rate per quarter, –0.12%; 95% CI, –0.16 to –0.07; P < .001). Following the black box warning, the decline continued (rate, –0.26%; 95% CI, –0.34 to –0.18; P < .001), with a significant difference between the early and black box warning periods (P = .006). Use of atypical antipsychotics as a group increased during the no-warning period (rate, 0.23; 95% CI, 0.17-0.30; P < .001), started to decline during the early-warning period (rate, –0.012; 95% CI, –0.14 to 0.11; P = .85), and more sharply declined during the black box warning period (rate, –0.27; 95% CI, –0.36 to –0.18; P < .001). Olanzapine and risperidone showed declining rates and quetiapine showed an increase during the early-warning period, but rates of use for all 3 antipsychotics declined during the black box warning period. In the black box warning period, there was a small but significant increase in anticonvulsant prescriptions (rate, 0.117; 95% CI, 0.08-0.16; P < .001).
Conclusions Use of atypical antipsychotics began to decline significantly in 2003, and the Food and Drug Administration advisory was temporally associated with a significant acceleration in the decline.
Author Affiliations: Department of Veterans Affairs, Ann Arbor Center of Excellence, Serious Mental Illness Treatment, Research, and Evaluation Center, Ann Arbor, Michigan (Drs Kales, Zivin, Kim, Valenstein, Chiang, and Blow and Mss Ignacio and Ganoczy); Department of Psychiatry (Drs Kales, Zivin, Valenstein, Chiang, and Blow and Ms Ignacio) and Center for Statistical Consultation and Research (Dr Kim), University of Michigan, Ann Arbor; Veterans Affairs Center for Medication Safety, Patient Safety Center of Inquiry, and Pharmacoepidemiologic/Outcomes Research, Hines, Illinois (Ms Cunningham); and the University of Southern California Keck School of Medicine, Los Angeles (Dr Schneider).
http://archpsyc.ama-assn.org/cgi/content/short/68/2/190
Helen C. Kales, MD; Kara Zivin, PhD; Hyungjin Myra Kim, ScD; Marcia Valenstein, MD; Claire Chiang, MD; Rosalindo Ignacio, MS; Dara Ganoczy, MPH; Francesca Cunningham, PharmD; Lon S. Schneider, MD; Frederic C. Blow, PhD
Arch Gen Psychiatry. 2011;68(2):190-197. doi:10.1001/archgenpsychiatry.2010.200
Context Use of atypical antipsychotics for neuropsychiatric symptoms of dementia increased markedly in the 1990s. Concerns about their use began to emerge in 2002, and in 2005, the US Food and Drug Administration warned that use of atypical antipsychotics in dementia was associated with increased mortality.
Objective To examine changes in atypical and conventional antipsychotic use in outpatients with dementia from 1999 through 2007.
Design Time-series analyses estimated the effect of the various warnings on atypical and conventional antipsychotic usage using national Veterans Affairs data across 3 periods: no warning (1999-2003), early warning (2003-2005), and black box warning (2005-2007).
Subjects Patients aged 65 years or older with dementia (n = 254 564).
Main Outcome Measures Outpatient antipsychotic use (percentage of patients, percentage of quarterly change, and difference between consecutive study periods).
Results In 1999, 17.7% (95% confidence interval [CI], 17.2-18.1) of patients with dementia were using atypical or conventional antipsychotics. Overall use began to decline during the no-warning period (rate per quarter, –0.12%; 95% CI, –0.16 to –0.07; P < .001). Following the black box warning, the decline continued (rate, –0.26%; 95% CI, –0.34 to –0.18; P < .001), with a significant difference between the early and black box warning periods (P = .006). Use of atypical antipsychotics as a group increased during the no-warning period (rate, 0.23; 95% CI, 0.17-0.30; P < .001), started to decline during the early-warning period (rate, –0.012; 95% CI, –0.14 to 0.11; P = .85), and more sharply declined during the black box warning period (rate, –0.27; 95% CI, –0.36 to –0.18; P < .001). Olanzapine and risperidone showed declining rates and quetiapine showed an increase during the early-warning period, but rates of use for all 3 antipsychotics declined during the black box warning period. In the black box warning period, there was a small but significant increase in anticonvulsant prescriptions (rate, 0.117; 95% CI, 0.08-0.16; P < .001).
Conclusions Use of atypical antipsychotics began to decline significantly in 2003, and the Food and Drug Administration advisory was temporally associated with a significant acceleration in the decline.
Author Affiliations: Department of Veterans Affairs, Ann Arbor Center of Excellence, Serious Mental Illness Treatment, Research, and Evaluation Center, Ann Arbor, Michigan (Drs Kales, Zivin, Kim, Valenstein, Chiang, and Blow and Mss Ignacio and Ganoczy); Department of Psychiatry (Drs Kales, Zivin, Valenstein, Chiang, and Blow and Ms Ignacio) and Center for Statistical Consultation and Research (Dr Kim), University of Michigan, Ann Arbor; Veterans Affairs Center for Medication Safety, Patient Safety Center of Inquiry, and Pharmacoepidemiologic/Outcomes Research, Hines, Illinois (Ms Cunningham); and the University of Southern California Keck School of Medicine, Los Angeles (Dr Schneider).
http://archpsyc.ama-assn.org/cgi/content/short/68/2/190
No comments:
Post a Comment
Note: only a member of this blog may post a comment.